MOTS-c vs Retatrutide
Overview
MOTS-c and Retatrutide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares MOTS-c and Retatrutide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| MOTS-c | Retatrutide | |
|---|---|---|
| Category | Weight Management & Metabolic | Weight Management & Metabolic |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | Research use only |
| Typical dosage | 5-10 mg | Clinical trials |
| Frequency | weekly | weekly |
| Reported benefits | Enhanced metabolism, improved insulin sensitivity, increased exercise capacity, longevity benefits | Enhanced weight loss beyond dual agonists, metabolic improvement |
| Reported side effects | Well-tolerated. Minimal reported side effects | Clinical trial phase |
Key differences
Primary use. MOTS-c is categorised under Weight Management & Metabolic, while Retatrutide falls under Weight Management & Metabolic. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. MOTS-c: not FDA-approved; compounding permitted with a prescription as of April 2026. Retatrutide: not FDA-approved; treated as a research compound.
Dosing. MOTS-c is typically dosed at 5-10 mg (weekly). Retatrutide is typically dosed at Clinical trials (weekly).
Can you stack them?
Some protocols combine peptides, but stacking MOTS-c and Retatrutide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between MOTS-c and Retatrutide?
- MOTS-c and Retatrutide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status. MOTS-c is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Retatrutide is not FDA-approved; generally classified as a research compound.
- What is MOTS-c used for?
- Mitochondrial optimization.
- What is Retatrutide used for?
- Investigational triple agonist (GIP/GLP-1/glucagon). TRIUMPH-1 Phase 3 (May 2026): 28.3% body weight loss at 80 weeks. FDA submission anticipated Q3–Q4 2026.
- Can you take MOTS-c and Retatrutide together?
- Some users combine peptides within a single protocol, but stacking MOTS-c and Retatrutide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is MOTS-c or Retatrutide FDA-approved?
- MOTS-c is not FDA-approved; compounding permitted with a prescription (as of April 2026). Retatrutide is not FDA-approved; generally classified as a research compound.
Read the full articles
- MOTS-c — full monograph: mechanism, research, dosing & references
- Retatrutide — full monograph: mechanism, research, dosing & references